A Phase 2 Randomized Double-blind Study of Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy vs Placebo with Pembrolizumab and Chemotherapy in Front-line Metastatic KEAP1/NRF2- mutated Nonsquamous Non-Small Cell Lung (NSCLC)

Brief description of study

The purpose of the study is to determine the safety and efficacy of telaglenastat in combination with pembrolizumab plus chemotherapy compared with placebo in combination with pembrolizumab plus chemotherapy as first-line treatment of patients with metastatic KEAP1- or NRF2-mutated nonsquamous Stage IV Non-Small Cell Lung Cancer (NSCLC). We want to know if one treatment is better than another.

Clinical Study Identifier: s19-01766

ClinicalTrials.gov Identifier: NCT04265534

Principal Investigator: Vamsidhar Velcheti.

Other Investigators: Mary Lynn R Nierodzik, Elaine Shum, Marissa Rybstein, Melissa L Martinez, David Mendoza, Abraham Chachoua, Joshua K Sabari, Edna Shifteh, Natalia Cherkassky, Elsa Bahiru, Jeffrey G Schneider, Cristian C Papazoglu Statescu, Virginia M Ferreira, Vania R. Baudin, Monica Rivera, Jennifer Wu.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies